Identifai Genetics Limited · ASX:ID1
Identifai Genetics — IPO Roadshow (October 2026)
35 slides from Identifai Genetics's IPO roadshow presentation, Oct 14, 2026
Slide 1: Revolutionising prenatal genetic screening
rsonal use only Revolutionising prenatal genetic screening I PO I NVE STOR PRE SEN TA TI ON OCTOBE R 20 26 Identifai Genetics Limited (ASX CODE: ID1) I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 2: Important notice and disclaimer
Important notice and disclaimer rsonal use only These presentation materials have been prepared by Identifai Genetics (Identifai or receive such presentation in accordance with the above restrictions and agree to be • are necessarily based upon a number of estimates and assumptions that, while Compa
Slide 3: Introducing Identifai Genetics
Introducing Identifai Genetics Developing a non-invasive way to A high-conviction example of how A high-conviction example of how rsonal use only identify congenital and genetic comprehensive fetal genomic information comprehensive fetal genomic information can support clinical action before can sup
Slide 4: The quest to non-invasively identify all genetic disorders
The quest to non- rsonal use only invasively identify all genetic disorders I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 5: Genetic Disease – A Global Concern
Genetic Disease – A Global Concern Alignment to UN Sustainable rsonal use only Development Goals 3–6% of all newborns worldwide are TARGET 3.2 TARGET 3.7 5 affected by a serious congenital 5 years or genetic disorder End all preventable deaths under Universal access to sexual and 5 years of age repr
Slide 6: Genuine unmet clinical need
Genuine unmet clinical need rsonal use only What is the problem with What’s the solution? genetic disease screening and intervention today? • Non-invasive, single blood sample taken only from the mother • Existing NIPT only addresses a • Accurate fetal genome very limited number of genes reconstruct
Slide 7: Windrose is an agile, all-in-one solution
Windrose is an agile, all-in-one solution rsonal use only 6-12 weeks +1 week +2 weeks +2 weeks Often prolonged to 20w+ Current 7 Screening Amnio/CVS on specific Expanded Carrier Screening Mother Test father for Process mutations on Mother POSITIVE same mutations (Window 15-20w GA) 10 weeks + 1 week
Slide 8: Cell-free DNA in pregnancy
Cell-free DNA in pregnancy During pregnancy, the maternal Noninvasive Prenatal rsonal use only bloodstream contains cell-free DNA (cfDNA) which is a mixture of Testing (NIPT) maternal and fetal cfDNA. Identifai is able to leverage small Maternal Bloodstream differences between maternal and fetal cfD
Slide 9: Identifai addresses actionable conditions
Identifai addresses actionable conditions | American College 296 Actionable genes of Medical Genetics guidelines rsonal use only Cohen et al. (The American Journal of Human Genetics, 2025) identified 296 actionable genes relevant to fetal, delivery, or neonatal intervention. 54 Treatable in utero 26
Slide 10: Pompe disease case study – early information can alter the care pathway
Pompe disease case study – early information can alter the care pathway rsonal use only A high-conviction Why Pompe is an ideal indicative case study Identifai proof point: prenatal Pompe detection example of how • Well-characterized autosomal recessive disorder: Pathogenic GAA variants Two affected
Slide 11: Identifai's Windrose: a machine-learning approach to prenatal detection
Identifai’s Windrose rsonal use only a machine-learning approach to prenatal detection of disorders 11 I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 12: Windrose process
Windrose process rsonal use only Simple blood draw at Machine Learning week 9 or after Core Algorithm 12 > > > cfDNA Sequencing Clinical report I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 13: Windrose
Windrose Identifai’s US-market oriented product rsonal use only Windrose Basic Windrose Monogenic Disorders 1 3 13 Chromosomal and Fetal Genetic Screening for Sub-chromosomal Conditions Recessive Disorders (Inherited) T13,T18,T21, 22q11.2, SCA, fetal sex 81420 Reimbursement - $784 Positive Carrier S
Slide 14: Windrose Market Positioning 2026
Windrose Market Positioning 2026 rsonal use only NIPT Scope Expanded & expanded Reflex 14 Expanded & Reflex Expanded Carrier Screening Basic Scope No CS 14 genes 20 genes 500 genes 700 genes I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 15: Validation efforts are ongoing; patent family already in place
Validation efforts rsonal use only are ongoing; patent family already in place 15 I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 16: Analytic Validity Clinical Trial
Analytic Validity Clinical Trial rsonal use only Recruiting Sites (US) Recruiting Sites (IL) 16 I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 17: High performance vs diagnostic gold standard (N=50)
High performance vs diagnostic gold standard (N=50) rsonal use only Study design reflected Correctly separates affected Works even when fetal DNA commercial lab process vs unaffected pregnancies signal is low (early pregnancy) and workflows 100% overall accuracy in detecting inherited disease 17 sta
Slide 18: A Comprehensive IP Portfolio
A Comprehensive IP Portfolio rsonal use only Basic Technology Patent 11 Patent Families Full Freedom to 10 years of (US20210340601A1) Operate Analysis accumulated know 18 Granted patents in US, China and Israel, 3 families at NP, 5 PCTs, 3 Completed how trade secrets Provisionals Accuracy Boosting a
Slide 19: The target addressable market is large
The target rsonal use only addressable market is large 19 I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 20: Windrose US Market
Windrose US Market $11B-$22B rsonal use only $2.5B 5.5M Pregnancies 0.8M in pregnancy Carrier annually (US) Screening tests (US) Windrose 20 $3.6B 1.2M carrier screening tests (0.4M not billed) Basic NIPT Market $1-2B (Ref NIH 2024) ~30% are undergoing NIPT testing I DE N T I F A I G E N E T I C S I
Slide 21: Windrose Market Positioning
Windrose Market Positioning rsonal use only Current rate of Market Leader identification out of total genetic conditions 24.6% >72.5% 21 I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 22: Identifai's development road map and go-to-market plan
Identifai’s rsonal use only development road map and go-to-market plan 22 I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 23: Identifai's 2026-2028 Road Map
Identifai’s 2026-2028 Road Map rsonal use only 2026 2027 2028 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Clinical CLIA certification Clinical Validation Study Clinical Utility Study 23 Windrose+ development Pipeline scale up R&D Windrose+ Design Freeze – Algorithm and Pipeline Ongoing additions Windrose Trans
Slide 24: Inocras Partnership model
Inocras Partnership model • Inocras Lab’s focus is on whole genome sequencing Locations rsonal use only • It specializes in Cancer and Rare disease, with more than 15,000 patient cases with 3 CAP/CLIA assays • CAP accredited, CLIA certified and ISO-certified San-Diego lab • Partners will collaborate
Slide 25: Go-To-Market – US
Go-To-Market – US Clinical Validity study rsonal use only Sample size: 600 Patients • GTM – US market • 50–100 patients per site, results report to patients • CLIA certification with Inocras Lab, San Diego for the Laboratory Developed Test (“LDT”) expected to commence in August 2026 *Additional lead
Slide 26: Pro forma capital structure, IPO timetable and comparable ASX-listed peers
Pro forma rsonal use only capital structure, IPO timetable and comparable ASX-listed peers 26 I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 27: Pro-Forma Capital Structure
Pro-Forma Capital Structure rsonal use only DESCRIPTION AMOUNT Total Pre-IPO shares on issue 141,979,023 Total Pre-IPO options on issue 10,954,616 Initial Public Offer (IPO) shares 50,000,000 Price $0.20 IPO amount raised $10,000,000 27 Total shares on issue post-IPO 191,979,023 Total options on iss
Slide 28: Identifai IPO Timetable
Identifai IPO Timetable rsonal use only EVENT DATE Lodgement of Prospectus with ASIC Wednesday 2nd September 2026 Exposure Period begins 2 Wednesday 2nd September 2026 Opening Date of the Public Offer Tuesday 8th September 2026 Closing Date of the Offer 3 Tuesday 29th September 2026 28 Receipt of AS
Slide 29: ASX-listed Peers
ASX-listed Peers rsonal use only Companies developing and COMPANY MARKET CAPITALISATION FIELD/REGULATORY COMMERCIALIZATION commercialising AI-driven diagnostics and targeting A$37.8 million Genetic disease (in utero) Commercial launch the US market (A$10 million IPO raise) - LDT CLIA Certification c
Slide 30: Identifai's leadership team and investment thesis
Identifai’s rsonal use only leadership team and investment thesis 30 I DE N T I F A I G E N E T I C S I P O P R E S E N T A T I O N
Slide 31: A well-respected team of industry professionals
A well-respected team of industry professionals rsonal use only 31 EYAL MILLER PROF. NOAM SHOMRON PhD NOA LISCOVITCH PhD GILAD MAGNAZI CEO CSO Head of R&D COO MBA, MA, with 27 years of global Head of the Functional Genomics Lab at PhD in Computational neuro-genomics with MEng in Systems Engineering,
Slide 32: Scientific, market and regulatory advisors
Scientific, market and regulatory advisors rsonal use only 32 ELENA ASHKINADZE DR. BERT GOLD DR. LISA BRAILEY Rutgers University Laboratory Director Physician-Scientist & Laboratory Director • Specialist in medical genetics and • Veteran molecular geneticist with • Deep expertise in clinical genetic
Slide 33: Board Members
Board Members rsonal use only 33 YOSEPH BORNSTEIN KOBI CASPI LUCY ROBB VUJCIC ATA GOKYILDIRIM Chairman Founder, President, and CEO of Partner, Director, and CFO of A commercial barrister and Non-Executive Director at BluGlass Shizim Group, Yoseph is a Shizim Group, with more than governance speciali
Slide 34: Key Factors Underpinning Identifai Genetics' Strong Growth Prospects
Key Factors Underpinning Identifai Genetics’ Strong Growth Prospects rsonal use only 34 Unmatched AI- Non-invasive and “Future proof” Comprehensive All In one approach – powered platform, early detection, platform – dynamic genome analysis - the able to provide capable of detecting reducing the need
Slide 35: Thank You
Thank rsonal use only You 35 IDENTIFAI GENETICS – INVESTOR RELATIONS Damian Black +61 411 166 530 corporate@aesircapital.com.au I PO I NVE STOR PRE SEN TA TI ON OCTOBE R 202 6 Identifai Genetics (ASX proposed: ID1) IDENTIFAI-GENETICS.COM RE VOLUTI ONI SING PRE NATAL GENE TIC SC RE EN ING I DE N T I